<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205320</url>
  </required_header>
  <id_info>
    <org_study_id>PG-01-003</org_study_id>
    <nct_id>NCT02205320</nct_id>
  </id_info>
  <brief_title>A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative pharmacokinetic, pharmacodynamic and safety study in healthy volunteers
      with three forms of pegylated granulocyte colony stimulating factors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>105 days</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>105 days</time_frame>
    <description>Area under concentration-time curve extrapolated from time 0 to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>105 days</time_frame>
    <description>Area under concentration-time curve from time 0 to the time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax</measure>
    <time_frame>105 days</time_frame>
    <description>Maximum observed effect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC(0-t)</measure>
    <time_frame>105 days</time_frame>
    <description>Area under the effect time curve from time zero (predose) to last measured time</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence I (DRL, A, B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence II (DRL, B, A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence III (A, DRL, B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence IV (A, B, DRL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence V (B, A, DRL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence VI (B, DRL, A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DRL_PG</intervention_name>
    <arm_group_label>Treatment Sequence I (DRL, A, B)</arm_group_label>
    <arm_group_label>Treatment Sequence II (DRL, B, A)</arm_group_label>
    <arm_group_label>Treatment Sequence III (A, DRL, B)</arm_group_label>
    <arm_group_label>Treatment Sequence IV (A, B, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence V (B, A, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence VI (B, DRL, A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim Form A</intervention_name>
    <arm_group_label>Treatment Sequence I (DRL, A, B)</arm_group_label>
    <arm_group_label>Treatment Sequence II (DRL, B, A)</arm_group_label>
    <arm_group_label>Treatment Sequence III (A, DRL, B)</arm_group_label>
    <arm_group_label>Treatment Sequence IV (A, B, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence V (B, A, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence VI (B, DRL, A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim Form B</intervention_name>
    <arm_group_label>Treatment Sequence I (DRL, A, B)</arm_group_label>
    <arm_group_label>Treatment Sequence II (DRL, B, A)</arm_group_label>
    <arm_group_label>Treatment Sequence III (A, DRL, B)</arm_group_label>
    <arm_group_label>Treatment Sequence IV (A, B, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence V (B, A, DRL)</arm_group_label>
    <arm_group_label>Treatment Sequence VI (B, DRL, A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects aged 18 to 55 years

          2. A standardized body mass index

          3. General good health as determined by the Investigator

          4. Normal organ function as per the Investigator's judgement

          5. Must be non-smokers, or ex-smokers who have not smoked within the previous 6 months
             from the screening visit

          6. Female subjects must:

               -  Not be lactating; not be pregnant

               -  Agree to use an acceptable contraceptive method or be of non-childbearing
                  potential

          7. Male subjects must refrain from donating sperm or fathering a child during the study
             and until 3 months after the last study drug

        Exclusion Criteria:

          1. Known hypersensitivity to Escherichia coli derived proteins, pegfilgrastim, filgrastim
             or any other related component

          2. Presence of antibodies to polyethylene glycol at screening

          3. Positive result for cotinine (&gt;500 ng/mL) or drugs of abuse at screening or on
             admission

          4. Prior history of or current alcohol abuse or excessive intake of alcohol as judged by
             the Investigator

          5. Donation of blood (â‰¥500 mL) or plasma within the previous 3 months

          6. History of unexplained syncopal episodes;

          7. Any disorder that, in the Investigator's opinion, may interfere with study compliance

          8. History of any cancer

          9. History of pulmonary infiltrate or pneumonia within the previous 6 months from
             screening visit

         10. Hereditary fructose and/or sorbitol intolerance

         11. Absolute neutrophil count below 1500/mm3 or above 12000/mm3 at screening

         12. Positive test for hepatitis B surface antigen, hepatitis C antibody, or human
             immunodeficiency virus (HIV) 1 or 2

         13. Any abnormality in 12-lead ECG that in the Investigator's opinion is clinically
             significant and/or suggestive of underlying cardiac abnormalities

         14. A clinical diagnosis of hypertension, significant hypercholesterolemia as judged by
             the Investigator, or thyroid abnormalities

         15. Family history of acute myeloid leukemia or subjects with splenomegaly at baseline, or
             with sickle cell disease

         16. Any prescribed or over the counter medications including analgesics, herbal remedies,
             vitamin therapy must not be used from 7 days prior to the first administration of
             study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QPS Bio-Kinetic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Morrison, DO</last_name>
      <phone>417-831-0456</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

